Personalized Circulating Tumor DNA Analysis as a Predictive Biomarker in Solid Tumors

Two medical oncologists summarize data on use of circulating tumor DNA as a predictive biomarker in solid tumor patients treated with pembrolizumab.

George Ansstas, MD, and Firas B. Badin, MD, discuss the potential clinical implications of using circulating tumor DNA as a predictive biomarker in solid tumor patients treated with immunotherapy.

CancerNetwork® recaps a Between the Lines journal club program with George Ansstas, MD, and Firas B. Badin, MD.